Tiziana Life Sciences LtdNASDAQ:TLSA
- LAST PRICE0.9522
- TODAY'S CHANGE (%)-0.0178 (-1.8351%)
- Bid / Lots0.9500/ 20
- Ask / Lots0.9900/ 91
- Open / Previous Close0.9800 / 0.9700
- Day Range
- 52 Week Range
- Volume101,519
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TLSA |
|---|---|---|
| 09:32 ET | 3189 | 0.98 |
| 09:37 ET | 1000 | 0.95 |
| 09:42 ET | 10000 | 0.9501 |
| 09:50 ET | 100 | 0.9501 |
| 10:02 ET | 4483 | 0.99 |
| 10:15 ET | 185 | 0.9504 |
| 10:24 ET | 200 | 0.9752 |
| 10:38 ET | 500 | 0.9508 |
| 10:42 ET | 540 | 0.9595 |
| 10:47 ET | 5025 | 0.97 |
| 10:49 ET | 100 | 0.97 |
| 10:51 ET | 1500 | 0.9604 |
| 11:02 ET | 151 | 0.9508 |
| 11:18 ET | 435 | 0.9508 |
| 11:21 ET | 100 | 0.9752 |
| 11:23 ET | 2650 | 0.954582 |
| 11:27 ET | 1000 | 0.963 |
| 11:38 ET | 1239 | 0.96 |
| 11:48 ET | 1000 | 0.9599 |
| 11:56 ET | 1500 | 0.96 |
| 11:59 ET | 3274 | 0.9598 |
| 12:01 ET | 100 | 0.96 |
| 12:06 ET | 500 | 0.9509 |
| 12:10 ET | 1191 | 0.9509 |
| 12:15 ET | 2000 | 0.96 |
| 12:19 ET | 200 | 0.9509 |
| 12:21 ET | 250 | 0.951 |
| 12:26 ET | 308 | 0.96 |
| 12:30 ET | 1000 | 0.95545 |
| 12:39 ET | 300 | 0.9519 |
| 12:44 ET | 242 | 0.96 |
| 12:50 ET | 100 | 0.96 |
| 12:51 ET | 183 | 0.96 |
| 01:02 ET | 300 | 0.96 |
| 01:09 ET | 1700 | 0.951 |
| 01:15 ET | 300 | 0.96 |
| 01:26 ET | 1200 | 0.9554 |
| 01:33 ET | 200 | 0.951 |
| 01:36 ET | 5100 | 0.96 |
| 01:40 ET | 200 | 0.9509 |
| 01:42 ET | 3129 | 0.9509 |
| 01:44 ET | 200 | 0.9509 |
| 01:45 ET | 206 | 0.95545 |
| 01:47 ET | 764 | 0.9508 |
| 01:49 ET | 800 | 0.959899 |
| 01:58 ET | 500 | 0.9599 |
| 02:25 ET | 5100 | 0.9599 |
| 02:45 ET | 600 | 0.9508 |
| 02:52 ET | 300 | 0.95535 |
| 02:56 ET | 11660 | 0.95 |
| 03:14 ET | 1653 | 0.9361 |
| 03:19 ET | 1273 | 0.958 |
| 03:33 ET | 2000 | 0.96 |
| 03:37 ET | 4166 | 0.9563 |
| 03:39 ET | 100 | 0.9563 |
| 03:42 ET | 3325 | 0.9582 |
| 03:44 ET | 700 | 0.9598 |
| 03:46 ET | 400 | 0.96 |
| 03:48 ET | 1800 | 0.95995 |
| 03:50 ET | 600 | 0.95995 |
| 03:57 ET | 400 | 0.9599 |
| 04:00 ET | 1733 | 0.9522 |
Nov 19, 2024
Tiziana Life Sciences Announces Groundbreaking ALS Trial Grant Awarded by the ALS Association, from 7:00AM ET on Tuesday Nov 19, 2024 by Dow Jones
7:00AM ET on Tuesday Nov 19, 2024 by Dow Jones
Nov 1, 2024
Oct 30, 2024
Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $10 Million, from 10:29PM ET on Wednesday Oct 30, 2024 by Dow Jones
10:29PM ET on Wednesday Oct 30, 2024 by Dow JonesPress Release: Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $10 Million, from 10:29PM ET on Wednesday Oct 30, 2024 by Dow Jones
10:29PM ET on Wednesday Oct 30, 2024 by Dow JonesTiziana Life Sciences Announces Positive Results from Ozempic and Nasal Anti-CD3 Combination Study, from 8:30AM ET on Wednesday Oct 30, 2024 by Dow Jones
8:30AM ET on Wednesday Oct 30, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Tiziana Life Sciences Ltd | 105.4M | -5.5x | --- |
Monopar Therapeutics Inc | 106.1M | -10.1x | --- |
Context Therapeutics Inc | 104.2M | -1.5x | --- |
CAMP4 Therapeutics Corp | 105.5M | -2.1x | --- |
INmune Bio Inc | 108.0M | -2.2x | --- |
Anixa Biosciences Inc | 103.0M | -8.2x | --- |
Company Information
Tiziana Life Sciences Ltd. is a United Kingdom-based clinical-stage biotechnology company. The Company develops transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for secondary progressive multiple sclerosis, Crohn's Disease and KRAS+ NSCLC. Its pipeline candidates include Foralumab (TZLS-401), Anti IL-6R mAb (TZLS-501) and Milciclib (TZLS-201). Foralumab (TZLS-401) is a fully human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn’s and neurodegenerative diseases. Its Anti IL-6R mAb (TZLS-501), a fully human mAb binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune disease and cancer, reducing circulating levels of the IL-6 cytokine. Milciclib is a potent, small molecule inhibitor of multiple cyclin-dependent kinases (CDKs), tropomycinreceptor kinases and Src family kinases controlling cell growth and malignant progression of cancer.
Contact Information
- Headquarters
- 3Rd Floor, 11-12 St. James's SquareLONDON, United Kingdom SW1Y 4LB
- Phone
- 207-495-2379
- Fax
- ---
Executives
- Executive Chairman of the Board
- Gabriele Cerrone
- Chief Executive Officer
- Ivor Elrifi
- Finance Director
- Keeren Shah
- Senior Director, CMC and Non - Clinical Development
- Jules Jacob
- Chief Development Officer
- William Clementi
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $105.4M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 110.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.44 |
EPS | $-0.17 |
Book Value | $0.05 |
P/E Ratio | -5.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
